NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis $7.96 -0.16 (-1.97%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.80▼$8.2950-Day Range$6.38▼$8.4652-Week Range$4.00▼$18.15Volume25,284 shsAverage Volume112,333 shsMarket Capitalization$228.99 millionP/E RatioN/ADividend YieldN/APrice Target$14.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NeuroPace alerts: Email Address NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside86.3% Upside$14.83 Price TargetShort InterestHealthy3.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 4 Articles This WeekInsider TradingSelling Shares$285,550 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.14) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.16 out of 5 starsMedical Sector377th out of 936 stocksSurgical & Medical Instruments Industry46th out of 101 stocks 3.4 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 2 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.14% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently increased by 223.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 2.4 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NeuroPace this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $285,550.00 in company stock.Percentage Held by Insiders22.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.14) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 10.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesJuly 23 at 4:05 PM | globenewswire.comNeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024July 23 at 5:11 AM | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of "Moderate Buy" by BrokeragesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | markets.businessinsider.comStrong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPaceMay 27, 2024 | finance.yahoo.comNeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 47% stake, while 24% is held by institutionsMay 14, 2024 | finance.yahoo.comNeuroPace to Participate in Two Healthcare Conferences in MayMay 13, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing ChallengesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 10, 2024 | markets.businessinsider.comNeuroPace’s Strong Q1 Performance and Promising Growth Prospects Affirm Buy RatingMay 9, 2024 | finanznachrichten.deNeuroPace, Inc: NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 8, 2024 | msn.comNeuroPace GAAP EPS of -$0.32May 8, 2024 | globenewswire.comNeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comNeuroPace is about to announce its earnings — here's what Wall Street expectsApril 20, 2024 | investing.comOrbiMed Advisors sells shares in NeuroPace worth over $238,000April 17, 2024 | globenewswire.comNeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024April 10, 2024 | fool.comNeuroPace (NASDAQ: NPCE)See More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees171Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$22.00 Low Stock Price Target$8.00 Potential Upside/Downside+87.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-45.61% Pretax Margin-45.61% Return on Equity-173.62% Return on Assets-30.89% Debt Debt-to-Equity Ratio4.05 Current Ratio6.43 Quick Ratio5.56 Sales & Book Value Annual Sales$65.42 million Price / Sales3.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book10.03Miscellaneous Outstanding Shares28,770,000Free Float22,382,000Market Cap$227.86 million OptionableOptionable Beta1.80 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Joel D. Becker (Age 56)CEO, President & Director Comp: $762kMs. Rebecca L. Kuhn (Age 63)CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary Comp: $614.91kDr. Martha J. Morrell (Age 67)Chief Medical Officer Comp: $728.68kMs. Leah AkinActing General CounselMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 55)Vice President of Human Resources More ExecutivesKey CompetitorsSanara MedTechNASDAQ:SMTIBeyond AirNASDAQ:XAIRPAVmedNASDAQ:PAVMPulse BiosciencesNASDAQ:PLSEEmbectaNASDAQ:EMBCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 34,059 shares on 7/26/2024Ownership: 0.118%Kent Lake Capital LLCSold 27,317 shares on 5/16/2024Ownership: 2.237%Hillsdale Investment Management Inc.Bought 11,750 shares on 5/11/2024Ownership: 0.041%Vanguard Group Inc.Bought 75,512 shares on 5/10/2024Ownership: 1.701%Acadian Asset Management LLCBought 47,215 shares on 5/10/2024Ownership: 0.164%View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions How have NPCE shares performed this year? NeuroPace's stock was trading at $10.31 at the beginning of 2024. Since then, NPCE shares have decreased by 22.8% and is now trading at $7.96. View the best growth stocks for 2024 here. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) posted its earnings results on Wednesday, May, 8th. The company reported ($0.32) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.32). The business earned $18.12 million during the quarter, compared to the consensus estimate of $18.12 million. NeuroPace had a negative net margin of 45.61% and a negative trailing twelve-month return on equity of 173.62%. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? Top institutional shareholders of NeuroPace include Bank of New York Mellon Corp (0.12%). Insiders that own company stock include Ltd Kck, Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell and Irina Ridley. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
